An observational study in Preeclampsia, Pregnancy Complications and Diabetes Mellitus in Pregnancy, sponsored by Charite University, Berlin, Germany. Recruiting at 1 site in Germany. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-08-14.
Sponsored by Charite University, Berlin, Germany · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Pre-Eclampsia with a site in Germany — 6 open to participants now, 6 under way, none of them phase 3. Pre-Eclampsia · Germany.
Among the 17 studies in Pre-Eclampsia with a site in Germany, this one has the largest planned enrollment of the 10 observational ones that give a count, is one of 3 that started in 2017, is one of 10 observational ones, and was the 7th registered.
916 studies on the registry are indexed under Pre-Eclampsia; 243 are open to participants now.
Browse Pre-Eclampsia studies →6 of the 17 studies in Pre-Eclampsia with a site in Germany are open now. Recruiting first, the newest first:
Heidelberg University · Sites in Germany
Ages 18+ · Women only · Healthy volunteers
Heidelberg University · Sites in Germany
Ages 18+ · Women only · Healthy volunteers
University Hospital Schleswig-Holstein · Sites in Germany
Ages 18+ · Women only
Charite University, Berlin, Germany · Sites in Germany
Ages 18–60 · Women only · Healthy volunteers
Charite University, Berlin, Germany · Sites in Germany
Ages 18–70 · Women only · Healthy volunteers
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 162 Pre-Eclampsia studies recruiting now, 81 (50%) set no upper age limit and 80 (49%) stop at 75 or younger; 18 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 45 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2017.
This study's planned enrollment of 1,580 is above the median of 165 across 397 observational studies indexed under Pre-Eclampsia.
Median enrollment 40 across the 7 interventional studies, 253 across the 10 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 17 have an industry lead sponsor. The 10 most frequent:
Charite University, Berlin, Germany is the lead sponsor of 857 studies on the registry; 129 are open to participants now.
Charite University, Berlin, Germany has 4 studies filed under Pre-Eclampsia — fewer than ten, so there is no comparison to draw.
3 of the studies in Pre-Eclampsia with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06912477Heidelberg UniversityEndothelial Dysfunction for Prognosis In Patients With preeClampSia | 2026-12 |
| NCT07106294Heidelberg UniversityHyperspectral Imaging for Prediction of Preeclampsia | 2027-07-01 |
| NCT03313024Charite University, Berlin, GermanyBerlin-Brandenburg Pregnancy Cohort | 2027-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 17 studies in Pre-Eclampsia with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will investigate the interplay of different immune cells and placental cells as well as their potential for the development of pregnancy complications. In particular, the translation of the uteroplacental syndrome into a maternal syndrome, considered in the multifactorial pregnancy disorder preeclampsia, will be investigated. Immune cell subtypes are causally involved in the formation and translation of preeclampsia by inducing an endothelial dysfunction which leads to cardiovascular damage.
Pregnant women between 18 and 45 years of age without infections, severe or chronic diseases
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
T cell population content at the time of preeclampsia diagnosis compared to controls and verified by flow cytometry
Time frame: at the time of preeclampsia diagnosis compared to controls at the same time point in pregnancy
Plan to share: Undecided
No publications or documents are linked to this record.
Started Sep 2017 (actual). Primary completion is estimated for Oct 2027, 121 months after the start.
Of 191 non-industry observational studies under Pre-Eclampsia, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 56. This study's planned 121 months is above that.
Counting every sponsor, half of 200 studies reached it within 30 months; a quarter within 11 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Charite University, Berlin, Germany →